Secukinumab in the Treatment of Hidradenitis Suppurativa
- 16 October 2023
- journal article
- research article
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (17) , 1449-1457
Abstract
The IL-17 pathways are involved in the pathophysiology of many inflammatory skin conditions, including hidradenitis suppurativa. Secukinumab, an IL-17A inhibitor, has been used for years in inflamm... Plain language summary Hidradenitis suppurativa is a chronic skin disorder characterized by recurrent painful bumps, tunnels underneath the skin and significant scarring. To date, the only US FDA-a... Tweetable abstract Secukinumab, an IL-17A inhibitor, has been used for years in inflammatory skin disorders such as psoriasis. We review its role in the treatment of hidradenitis suppurativa (HS).Keywords
Funding Information
- National Psoriasis Foundation.
This publication has 38 references indexed in Scilit:
- Two Phase 3 Trials of Adalimumab for Hidradenitis SuppurativaNew England Journal of Medicine, 2016
- Pathophysiology of hidradenitis suppurativa: An updateJournal of the American Academy of Dermatology, 2015
- HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab studyJournal of the European Academy of Dermatology and Venereology, 2015
- Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)Journal of the European Academy of Dermatology and Venereology, 2014
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)British Journal of Dermatology, 2014
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 TrialsNew England Journal of Medicine, 2014
- Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1βBritish Journal of Dermatology, 2011
- Deficiency of IL-22 Contributes to a Chronic Inflammatory Disease: Pathogenetic Mechanisms in Acne InversaThe Journal of Immunology, 2011
- Increased Serum Tumour Necrosis Factor- in Hidradenitis Suppurativa Patients: Is There a Basis for Treatment with Anti-Tumour Necrosis Factor- Agents?Acta Dermato-Venereologica, 2009
- Regulating Off-Label Drug Use — Rethinking the Role of the FDANew England Journal of Medicine, 2008